LINCOLN, Mass., Oct. 11, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that they will deliver a presentation and poster at the 7th annual World ADC conference on the use of quantitative systems pharmacology (QSP) modeling to understand the pharmacokinetics (PK) of antibody drug conjugate (ADC) therapeutics.
Dr. Joshua Apgar, PhD, Co-Founder, CSO of Applied BioMath, will deliver a talk titled "Computational Exploration of Mechanistic Determinants of ADC Pharmacokinetics Using QSP Modeling Strategies" on Wednesday October 12, 2016. This presentation will mark the first time ever that QSP modeling for ADC therapeutics has been presented at the World ADC conference.
"World ADC strives to provide scientists with the latest insights on innovative advances in antibody drug conjugate research and development. It is for this reason that we are particularly looking forward to Dr. Joshua Apgar's presentation on ADC pharmacokinetics using QSP modelling strategies as this will be the first time ever that this topic has been covered at a World ADC event."
Curtis Dingley, World ADC Leadership Team, Hanson Wade
The PK of ADC therapeutics typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules. This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex. Dr. Apgar will present how model aided drug invention provides biological insights into the impact of drug-to-antibody ratio and the resulting changes in molecular properties on overall PK and relative payload disposition as observed in preclinical and clinical studies.
"We constantly strive to be at the forefront of QSP modeling, which is why we are so excited to be a part of this first ever presentation on QSP modeling at World ADC 2016. Our research has resulted in some very exciting insights into the PK of ADC therapeutics that will be of great interest to the ADC crowd at this conference."
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D. Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward. Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug. We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
SOURCE Applied BioMath